Gulf Pharmaceutical
Gulf Pharmaceutical Industries, commonly known as Julphar, is a leading pharmaceutical company headquartered in the United Arab Emirates (AE). Established in 1980, Julphar has grown to become a prominent player in the Middle East and North Africa (MENA) region, focusing on the development, manufacturing, and distribution of high-quality pharmaceutical products. With a diverse portfolio that includes prescription medications, over-the-counter products, and biotechnology solutions, Julphar is renowned for its commitment to innovation and quality. The company has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities and a robust research and development programme. Julphar's dedication to excellence has positioned it as a trusted name in the pharmaceutical industry, contributing to improved healthcare outcomes across its operational regions.
DitchCarbon Score
How does Gulf Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gulf Pharmaceutical's score of 20 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Gulf Pharmaceutical's reported carbon emissions
In 2023, Gulf Pharmaceutical Industries (Julphar), headquartered in the UAE, reported total carbon emissions of approximately 35,100 kg CO2e. This figure includes about 6,300 kg CO2e from Scope 1 emissions and about 29,400 kg CO2e from Scope 2 emissions. Over the past few years, Julphar has demonstrated a commitment to reducing its carbon footprint, with emissions decreasing from approximately 36,300 kg CO2e in 2021 and 35,800 kg CO2e in 2022. Despite these reductions, there are currently no specific reduction targets or climate pledges disclosed by the company. The absence of Scope 3 emissions data indicates a potential area for future focus, as many companies in the pharmaceutical industry are increasingly addressing their entire value chain's emissions. Julphar's ongoing efforts to monitor and report its emissions reflect a growing awareness of climate impact within the sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 8,417,000 | 0,000,000 | 0,000,000 | 0,000 | 0,000 | 0,000 | 0,000 |
| Scope 2 | 33,350,000 | 00,000,000 | 00,000,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gulf Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
